These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22905596)
21. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. Dahl R; Kapp A; Colombo G; de Monchy JG; Rak S; Emminger W; Riis B; Grønager PM; Durham SR J Allergy Clin Immunol; 2008 Feb; 121(2):512-518.e2. PubMed ID: 18155284 [TBL] [Abstract][Full Text] [Related]
22. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Powell RJ; Frew AJ; Corrigan CJ; Durham SR Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551 [TBL] [Abstract][Full Text] [Related]
23. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501 [TBL] [Abstract][Full Text] [Related]
24. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy. Senna GE; Calderon M; Milani M Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of sublingual immunotherapy with grass monomeric allergoid: comparison between two different treatment regimens. Quercia O; Bruno ME; Compalati E; Falagiani P; Mistrello G; Stefanini GF Eur Ann Allergy Clin Immunol; 2011 Dec; 43(6):176-83. PubMed ID: 22360134 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374 [TBL] [Abstract][Full Text] [Related]
27. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093 [TBL] [Abstract][Full Text] [Related]
28. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937 [TBL] [Abstract][Full Text] [Related]
30. Sustained clinical efficacy of sublingual immunotherapy with a high-dose grass pollen extract. Kuna P; Samolinski B; Worm M; Pfaar O; Klimek L; Eur Ann Allergy Clin Immunol; 2011 Aug; 43(4):117-21. PubMed ID: 21980799 [TBL] [Abstract][Full Text] [Related]
31. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126 [TBL] [Abstract][Full Text] [Related]
32. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808 [TBL] [Abstract][Full Text] [Related]
33. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030 [TBL] [Abstract][Full Text] [Related]
34. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Kleine-Tebbe J; Ribel M; Herold DA Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193 [TBL] [Abstract][Full Text] [Related]
35. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Eng PA; Borer-Reinhold M; Heijnen IA; Gnehm HP Allergy; 2006 Feb; 61(2):198-201. PubMed ID: 16409196 [TBL] [Abstract][Full Text] [Related]
36. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. Roberts G; Hurley C; Turcanu V; Lack G J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125 [TBL] [Abstract][Full Text] [Related]
37. Comparison of Six Different Allergen Extracts for Subcutaneous Specific Immunotherapy in Children: An Open-Labelled, Prospective, Controlled Observational Trial. Kopp MV; König IR; Friedrichs F; Umpfenbach HU; Niggemann B; Millner-Uhlemann M Int Arch Allergy Immunol; 2019; 180(4):284-290. PubMed ID: 31665735 [TBL] [Abstract][Full Text] [Related]
38. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092 [TBL] [Abstract][Full Text] [Related]
39. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. Walker SM; Pajno GB; Lima MT; Wilson DR; Durham SR J Allergy Clin Immunol; 2001 Jan; 107(1):87-93. PubMed ID: 11149996 [TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Meyer W; Narkus A; Salapatek AM; Häfner D Allergy; 2013 Jun; 68(6):724-31. PubMed ID: 23621350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]